7 Steps for Human Variant Analysis

(and How to Automate Them!)





ABOUT DNASTAR

DNASTAR is a pioneer in the field of bioinformatics, offering comprehensive software solutions for molecular biology, genomics, transcriptomics, and protein analysis. Our Lasergene Genomics software enables you to set up complex genomic sequencing projects in mere minutes and automates tasks that typically require extensive manual intervention in other software packages.

About Genomenon

Genomenon is an AI-driven genomics company that organizes the world's genomic knowledge to connect patient DNA to scientific research in the diagnosis and development of treatments for patients with rare genetic diseases and cancer. Genomenon's Mastermind Genomic Search Engine powers variant interpretation by reducing turnaround time, increased diagnostic yield, and lowering the risk of missing a patient diagnosis.

Introd	UCT	on

Chapter 1: Step-by-Step Variant Analysis Procedure	5
 Preliminary Steps Step 1: Import & clean up sequencing data Step 2: Align reads to a reference genome Step 3: Remove PCR duplicates Step 4: Call variants and INDELS Step 5: Filter data to discover important variants Step 6: Determine how variants affect genes Step 7: Visualize the impact of the variant on the 3D protein structure 	7 8 9 9 10 11 12
Chapter 2: Using Lasergene Genomics + Mastermind Genomic Search Engine to Streamline Variant Analysis	13
Chapter 3: Use Case with Lasergene Genomics & Mastermind Genomic Search Engine	21
Conclusion	29

3

Introduction

In this ebook, we discuss some of the challenges involved in human variant analysis and explore some of the solutions available for addressing these challenges. Whether you are working with a core facility, a bioinformatics group, or doing variant analysis on your own, this ebook will help you learn about important considerations to keep in mind throughout the process.

Why study variants?

A common workflow in the study of human genetic variation involves the analysis and identification of deleterious variants or of variants associated with a particular population or trait. There are thousands of known variants that cause Mendelian disorders, and thousands more whose molecular basis is yet unknown.

In a typical human variant analysis study, the researcher's goal is to identify which single-nucleotide polymorphisms (SNPs), small insertions and deletions (INDELs), copy number variations (CNVs), or other types of structural variations and rearrangements (SVs) have functional significance. Functionally significant variants are those that cause amino acid changes, abnormal exon splicing, or other protein structure changes that contribute to a diseased state.

Challenges in variant analysis

The path from raw DNA reads to an understanding of the clinical significance of their variants can be long and complex. Each step and application will affect the accuracy and completeness of the results. An additional complication is that the large number of tools available have led to a myriad of pipelines. Just analyzing one data set can require mastery of up to a dozen bioinformatics applications and online databases.

Another challenge is that many open-source tools are created and then abandoned as graduate students finish their bioinformatics dissertations or laboratories lose funding or change focus. Few of these tools provide comprehensive documentation or instruction.

Even supposedly "automated" open source and commercial pipelines may rely on command line utilities at some of the key steps or require you to navigate through multiple "wizards" at each step in the pipeline. These additional steps generate multiple intermediate data files and increase hands-on time and clock time from raw data to the data analysis steps. It is therefore important to assess your ability and willingness to enter a pipeline that may require the use of command line tools and at least intermediate knowledge of bioinformatics.

Chapter 1


Step-by-Step Variant Analysis Procedure

There is no universally agreed upon number of steps involved in variant analysis, and some projects require more steps than others. In this ebook, we have divided the bioinformatics portion of the workflow into **seven steps** based on when you would typically need to switch from one tool to the next to keep advancing through the pipeline.

If you have bioinformatics expertise, you can build these steps into an automated or semi-automated pipeline using scripting and open-source tools. Note that some commercial variant analysis software packages combine two or more of these steps into a single process. If you are working with a core facility, they may have their own pipeline that covers some or all of these steps before delivering the data to you.

If you are new to variant analysis, be sure to do your research and have a plan in place to make sure that the output from one step is readable by the next tool along the path. If a core facility or bioinformatics group is doing some of this work for you, you'll want to understand what data they will be delivering to you so you can plan your next steps accordingly.

Variant Analysis Overview



Preliminary Steps

Choose a sequencing strategy and prepare samples

While this ebook focuses primarily on the bioinformatics and data analysis steps involved in studying human variants, there are many important decisions you will need to make before you can dive into the data. How you design and execute your sequencing strategy will greatly impact the quality of your data, so be sure to consider your analysis goals before beginning your experiment.

Before obtaining DNA samples, first determine if you will be doing a germline or somatic analysis. Somatic analysis compares samples from related tissues from a single individual and is often used in cancer research. Germline analysis, by contrast, compares samples from different individuals that may be heterozygous or homozygous for a trait.

Another consideration is whether you will be doing whole-genome, whole-exome, or RNA sequencing. All of these can yield important results and help elucidate the genetic cause of a disease. RNA-Seq is useful when you want to study differences in gene expression rather than simply the presence or absence of a SNP in the DNA sequence. Whole-genome sequencing (WGS) is not typically used in the case of human subjects. One reason is that it is prohibitively expensive for most researchers, although costs have come down substantially. Another concern is that the significance of non-coding variants is typically much more difficult to determine than coding changes and their abundance (~400x more than in coding regions) makes data handling and analysis more cumbersome and inefficient. Technological improvements and cost reductions are making WGS a more viable option when needed.

Because of the issues mentioned here, whole-exome sequencing, which considers only the \sim 1-2% of DNA that codes for proteins, is much more common than whole-genome sequencing for variant analysis studies. One caveat to be aware of is that exome capturing kits may miss some regions of interest, potentially missing important variants.

Once you have obtained the appropriate human DNA, each sequencing platform (e.g., Sanger, Illumina, Ion Torrent, PacBio, Oxford Nanopore), will have their own wet-lab protocols for sample preparation specific to the technology. For example, short read sample preparation typically requires fragmentation and PCR amplification steps, while long read preparation avoids DNA fragmentation at all costs. If you would like to enhance mapping accuracy and identify structural rearrangements with more clarity, consider a technology that produces long reads, paired-end, or mate-pair reads.

The final preliminary step is the actual sequencing, which is typically performed at a dedicated sequencing facility.

Bioinformatics Steps

After sequencing is complete and you have sequence data in FASTQ format or variant call format (VCF), you are ready to start your analysis. The remaining steps all come down to your bioinformatics software and your ability to utilize it. Keep in mind that some of these steps may have been completed before you receive your data.

Step 1: Import & clean up sequencing data

If your data files are in FASTQ format, this step is where you'll jump in and upload the file(s) into a software application for assessment and possible clean-up.

NGS data files (Illumina and Ion Torrent) are typically cleaned up using the pipeline tools associated with the sequencing instrument. This is normally sufficient. However, some output sequence files can benefit from scanning with a third party tool like FastQC. FASTQ files? Here's your starting point

Sanger data, by contrast, is not typically cleaned up during sequencing. Sanger data usually contains many base calling errors at the 5' and 3' ends where the chromatogram peaks are not high quality. This type of data requires a high-quality software program that can accurately trim the sequence ends,

Step 2: Align reads to a reference genome

This step involves using a computer program to align/map the read sequences to an existing reference genome; this is usually followed by a local realignment. The two most widely used public sources for human reference genomes are the Genome Reference Consortium (GRC), which provides GRCh36 through GRCh38, and the University of Santa Cruz (UCSC), which provides versions hg18 and hg19.

Image: State of the state of	A T T A G A A A C A C C C A A A C C A G T A A 32,110 32,120
ID_4551790_f_dup[2] 🛏	ATTAGAAACACCCAAACCAGTAA
ID_71704380_r →	ATTAGAAACACCCAAACCAGTAA
ID_21065922_f_dup[5] →	ATTAGAAACACCCAAACCAGTAA
ID_5492032_r_dup[2] ←	ATTAGAAACACCCAAACCAGTAA
ID_16407916_r_dup[2] ←	ATTAGAAACACCCAAACCAGTAA

Some popular tools used for alignment include SOAP, Bowtie/Bowtie2, BWA, and MOSAIK. The results of the alignment are generally saved as BAM or CRAM formatted files.


Step 3: Remove PCR duplicates

When performing whole-genome or whole-exome sequencing, PCR duplicates should be removed immediately after the alignment step. This prevents duplicate reads that originate from a single template from interfering with later variant calling statistics. Commercial solutions may automatically detect and remove duplicate reads from the variant caller. One tool that can be used for this purpose is Picard Tools, though it works only with BAM files.

Step 4: Call variants and INDELS

Variant calling is the process of comparing the aligned read sequences to the reference sequence in order to find locations where they disagree. The four main types of variants are:

- Single-nucleotide polymorphisms (SNPs)
- Small insertions and deletions (INDELs)
- Larger indels, known as "structural variations" (SVs)
- Copy number variations (CNVs), in which a section of DNA is repeated multiple times



Scores of variant callers are available and are generally classified into four groups:

- **Germline callers** (including CRISP, SAMtools, GATK), typically used for elucidating the causes of rare diseases.
- **Somatic callers** (Including GATK, SomaticSniper), the choice used in most cancer studies.
- Copy number variation (CNV) finders (including CONTRA, CNVnator, RDXplorer). CNVs can be detected in both whole-genome and whole-exome assemblies, which is not true of other structural variations.
- **Non-CNV structural variation (SV) finders** (including ExomeCNV, CONTRA) are used to find inversions, translocations or large INDELs.

It is critically important to choose the right variant caller for your data. Using the wrong variant calling pipeline can lead to missed variant calls. In addition, different variant callers have been shown to work better with different types of sequencing technology.

After alignment and variant calling, the limited number of applications that can perform sample crossnormalization or that can utilize a BED file to filter the variant list will perform those steps now.

The output from GATK and other variant calling pipelines is a Variant Calling Format (VCF) file. VCF is a scalable, tab-delimited text file with specific rules pertaining to the order and contents of columns. Each row represents a single nucleotide variant (SNV), insertion, deletion, or other sequence variation. Each variant is uniquely identified with a unique combination of letters and numbers, and the file may contain identifiers from multiple databases.

Step 5: Filter data to discover important variants

If Steps 1-4 didn't sound familiar or relevant to your experience, that's because they are frequently performed by a core facility or bioinformatics group. This step—which may start with the import of one or more VCF files—is the first one in which most researchers become directly involved.

VCF files? Jump in here!

All sequencing platforms produce sequence reads that contain many base-level errors, and it is crucial to apply filtering that can separate "sequencing noise" from the variant "signal." Much of this baseline filtering can be done in an automated fashion, preferably using statistical confidence measures, but some may require you to run some initial "noise filtering" tools.

Even after filtering out sequencing errors, a typical human exome set will still contain thousands of variants. You must now rely on additional criteria, typically imported into the analysis pipeline, to differentiate the uninteresting variants from those that have functional or clinical significance. Some open-source tools that support filtering are VCF Tools and SnpSift.

Many filtering strategies can be used, but here are four examples:

- Filter out **synonymous SNPs.** Since these SNPs encode for the normal amino acid, they will not result in a deleterious effect.
- In the case of a whole-genome study, filter out variants located in non-coding regions.
- Filter out common alleles. For example, we can reasonably assume that a mutation that causes a rare kidney disease will be rare in the human population. Thus, if a SNP is common (i.e., has a high allele frequency) across a population, it is unlikely to be the cause of the rare disease and can be removed from consideration.
- Some cloud-based tools (e.g., the Integrative Genomics Viewer) and standalone applications (CLC Bio, Lasergene) let you compare variants from multiple VCF files. For instance, to find variants related to a particular form of brain cancer, you could filter out variants found in both brain cancer patients and controls and focus on variants found only in the cancer patients.

Step 6: Determine how variants affect genes

The goal of this step is to determine the functional and clinical consequences of variants and how they impact genes. This is best accomplished with data tables that contain both variant and functional information for one or multiple samples and which have the ability to easily verify variant calls by visualizing the assembled sequence reads. This is most often done using genome browsers, which are available in standalone and web-based versions.

A benefit to **standalone browsers** is that most provide a graphical user interface (GUI) which can support zooming, easier visualization, and the ability to browse interactively. One drawback, however, is that you may be responsible for importing a large number of different data tracks for each of your samples. In addition, cross-comparison and analysis of multiple samples may be challenging, depending on the analysis tools that are available.

One advantage to **web-based genome browsers** (e.g., Ensembl, UCSC Genome Browser, ANNOVAR, AnnTools, VariantAnnotation, NGS-SNP, and snpEff) is that you do not usually need to download or update a human variant annotation database. On the other hand, you must upload your own proprietary data to a remote server, which is not a viable option for all organizations, owing to data privacy policies. Furthermore, some of these tools are command-line driven and can require typing multiple long strings of text into the command-line interface.


At a minimum, a genome browser should allow you to display the aligned reads, see variants clearly (e.g., by displaying them in a different color), view annotation information, and visit the corresponding public database (e.g., Ensembl, the GWAS Catalog, EVA, UniProt, dbSNP, ClinVar) entries online via hyperlinks. Most tools only allow visualization of SNPs, while a few also support viewing CNVs and SVs. Some genome visualization tools allow you to compare sequences from multiple individuals or even multiple organisms.

Once you have tabulated a list of variants, you may identify some for which there is limited data. Most search engines cannot excavate any further than paper titles and abstracts, where 85% of variants are not mentioned. This represents an enormous lost opportunity. While the crowd-sourced ClinVar platform is a useful repository of variant interpretations and related information, it is far from complete. In fact, an average of 31% of submitted references per variant are false-positives, with 30% of submissions having no references at all. Together, the downstream effects of these statistics can be serious, and may result in erroneous conclusions and/or a missed diagnosis. To mitigate these information quality issues, a deeper analysis can be performed using the Mastermind Genomic Search Engine, which is discussed in detail in Chapter 3.

Step 7 (Optional): Visualize the impact of the variant on the 3D protein structure

An optional step in the variant analysis pipeline is to attempt to determine the effect of a given variant on the 3D structure of the protein it codes for. Sometimes, the 3D structure may be minimally affected, if at all. In other cases, the variant can cause a dramatic change in protein structure, vitally impacting protein function.

Tools like I-Mutant and SDM can predict how the variant might affect protein stability, while structure prediction tools like I-TASSER and Phyre2 can predict the effect on protein structure. However, the latter tools will only work if a structural homolog is available. In some cases, you may find that the structure of the variant protein has already been determined through x-ray crystallography and is available for download through the Protein Data Bank (PDB). You can view these structures through various programs, including the LiteMol viewer.



An easier option is to use DNASTAR's Protean 3D application to accomplish all these tasks. Protean 3D's "Protein Design" workflow lets you use a wizard to easily "mutate" one or more residues and then calculates whether the changes are likely to be stabilizing or destabilizing compared to the original structure. NovaFold, a separately-licensed application that runs through the Protean 3D interface and is powered by the award-winning I-TASSER algorithm, can be used to predict the new protein structure caused by the mutated residue(s). Protean 3D lets you view the original and mutated proteins as fully customizable and rotatable 3D structures.

Chapter 2

Using Lasergene Genomics + Mastermind Genomic Search Engine to Streamline Variant Analysis

HOW IT WORKS

With **Lasergene Genomics** and **Mastermind**, just three applications are required to get meaningful variant results. Once you've identified variants of interest, you have the option to do further downstream analysis and visualization in Lasergene.



Import and assemble reads or VCF files with auomatic variant calling. Filter data to discover important variants and determine how variants affect genes. Mastermind Determine clinical significance of variants.

This is the complete package, from assembly to analysis"

Marjorie Beggs, Arkana Laboratories

The **Lasergene Genomics** variant analysis pipeline is completely different from the open-source software or other commercial software described in Chapter 1. How?

Instead of using separate tools and requiring multiple manual interventions at each step, Lasergene fully automates most of these steps into one easy wizard-based application: **SeqMan NGen**. The steps below will take longer to read than to perform, as it typically only takes about **2 minutes** to make selections and begin the assembly and variant calling. After this, variant analysis is performed using **ArrayStar and Mastermind**, with optional analysis and visualizations in other fully-integrated Lasergene applications.

Getting Started: Assembly and Variant Calling in SeqMan NGen

After launching **SeqMan NGen**, the Workflow screen (**Figure 1**) prompts you to choose a workflow. Select either the Variant Analysis/Resequencing workflow or the RNA-Seq/Transcriptomics workflow if you have raw sequence read data; or the Variant Call Format (VCF) File workflow if your data has already been assembled and the variants detected and saved to VCF format.




Figure 1. SeqMan NGen's multi-tabbed Workflow screen is the starting point for the project.

15

The SeqMan NGen wizard will guide you through the setup for one or multiple samples, auto-grouping and auto-naming FASTQ input files so that assembly (or VCF import), variant detection, variant filtering, sample cross comparison, and variant annotation are all run autonomously. SeqMan NGen supports a wide variety of file types and read technologies.

You can choose to import a custom VCF file and/or BED file to incorporate into your assembly. Adding these files now means the assembled project will include known variants of interest and defined targeted regions, respectively. This information can be used as filtering criteria without requiring you to import additional data after assembly.

Choose to upload a reference sequence or use one of the curated Genome Template Packages provided for common model organisms, including many versions of the human genome (**Figure 2**). The Genome Template Packages include both annotated reference chromosomes and the dbSNP database.

Organism 4	dbSNP Build	Assembly	Download Size	- ·
Apis mellifera	149	Arrel_4.5	129.9 MB	
Arabidopsis thaliana	138	TAIR10	87.1 MB	
Bos taurus	148	UMD_3.1.1	1.8 GB	
Caenorhabditis elegans	138	WS195	54.8 MB	
Canis lupus familiaris	146	3.1	1.1 GB	
Danio rerio	142	Zv9	729.0 MB	
Drosophila melanogaster	149	Release_6_plus_ISO	108.6 MB	
Equus caballus	151	EquCab2.0	1.1 GB	
Escherichia coli K12 MG1655	-	ASM584v2	3.1 MB	
Gallus gallus	147	5.0	625.6 MB	
Homo sapiens	150	GRCh37.p13	4.9 GB	
Homo sapiens	150	GRCh38.p7	3.5 GB	
Homo sapiens - Ensembl w/PDB	150	GRCh38.p10 + Ense	3.5 GB	
Homo sapiens mitochondrion	150	GRCh38.p7	33.3 kB	
Homo sapiens, CEU reference	142	GRCh37.p10	3.8 GB	
Homo sapiens, CHBJPT reference	142	GRCh37.p10	3.8 GB	
Homo sapiens, YRI reference	142	GRCh37.p10	3.8 GB	

Figure 2. A partial list of SeqMan NGen's available genome packages.

In the Analysis Options screen (**Figure 3**), choose variant calling options (diploid, haploid, somatic), gender, and initial variant filtering. Check the variant annotation database (VAD) box to automatically annotate any found variants with data from multiple databases, including Mastermind citation counts and hyperlinks to the Mastermind Genomic Search Engine.

Figure 3. SeqMan NGen "Analysis Options" wizard screen.

SeqMan NGen

Analysis Options Set the options for a post-assembly analysis Workflow Detect SNPs and other small variants V Reference Sequence Input Sequences Variant detection mode: O Diploid O Haploid O Somatic / cancer / heterogeneous Assembly Options Analysis Options Gender: Unknown ~ Assembly Output SNP filter stringency: O High O Medium O Low Annotate with the Variant Annotation Database (VAD) Includes: Mastermind literature citations from Genomenon 1000 Genomes Project and Exome Variant Server allele and genotype frequencies dbNFSPv4.1 (Clinvar, SIFT, GERP++, more...) Variant Annotation Database FAQ

You can also opt to detect CNVs and/or SVs. Choosing these options produces an assembly project that includes assembled data, filtered variant calls, CNVs, SVs, and extensive variant annotations.

Follow the guided steps to initiate assembly locally or on the cloud. Once assembly is complete, proceed to open the project in **ArrayStar** to analyze the results.

III ArrayStar and QSeq - OVCAR_TMEv2D_t38_cloud.astar*								
File Edit Filter Data Clustering Graphs Statistics View Help								
SNP Table Experiment List								
Experiment List								
🍢 · 🕼 · 🖉 📔 📫 🗰 🔅 🗙 🍃 🖻 🗥 1								Ту
Setting up your project.	SNP Table - 0	OVCAR_TMEv2	D_t38_cloud.asta	r				≖ ×
Do you have experiment attributes to import?	₽à @ 📐 🕈	S) 🗳 - 🏌	3 Add/Manage Co	olumns 🚃 Choose Quie	ck-Filter: Showing Seq	Man NGen Default Variants 👻	Type here to search	Q • 🕝 💂
Do you need to create/edit custom experiment attributes? Do you need to create replicate sets?	🗸 Ref ID	Ref Pos	Gene Name			2D_OVCAR_2D_rep1 Variant - MutationTaster_pred	2D_OVCAR_2D_rep1 ^ Variant - clinvar_clnsig	SNP Table SNP % ≥ ^ 15.00% and ≤
Do you need to create replicate sets?	NC 000019.	1218501	STK11	A>G	STK11	Disease causing (D)	Pathogenic	100.00% and s
Getting started with analysis.	NC 000011.	119089989	HMBS	G>A	HMBS	D;D;D;D;D;D;D	Pathogenic	Depth ≥ 20
Getting started with analysis.	NC 000002.	47410373	MSH2	G>A	MSH2	D;D;D	Pathogenic	
🛛 🖕 Would you like to begin filtering to find gene sets of interest?	NC 000002.	219282062	DNAJB2	G>A	DNAJB2	D;D	Pathogenic	
	NC 000017.	75522000	TSEN54	G>T	TSEN54	Disease causing - automatic (A)	Pathogenic/Likely	Details
Would you like to see a scatter plot?	NC 000021.	<u>9</u> 43063899			CBS	D;D;D;D;D;D;D;D;D;D;D;D	Pathogenic/Likely	Selected variant:
would you like to see a scatter plote	NC 000011.					D;D	Pathogenic/Likely	NC_000001.11 @
	<u>NC 000009.</u>				ENG	D;D;D;D	Pathogenic/Likely	14464
RNA-Seq	NC 000006.			C>T		D;D;D;D;D	Pathogenic/Likely	1 selected
a a 2D 2D 2D	□ <u>NC 000010.</u>				STOX1	P;P;P;P;P	Risk factor	variant:
2D_OVCAR_2D_rep2	□ <u>NC 000001.</u>			C>T	RNASEL	P(P)P	Risk factor	Ref ID: NC_ 000001.11
D 2DOVCAR_2D_rep3	□ <u>NC 000014.</u>				KLC1,XRCC3	P;P;P;P;P;P;P;P;P;P;P;P	Risk factor	Ref Pos: 14464
I I I I I I I I I I I I I I I I I I I	□ <u>NC 000014.</u>					D;D	Risk factor	Ref Seq: A Gene Name:
TME_OVCAR_TME_rep1	NC 000011.					D;D	Risk factor	WASH7P
TME_OVCAR_TME_rep2	NC 000017.		NLRP1			P;P;P;P;P;P	Risk factor	(pseudo) dbSNP ID;
TME_OVCAR_TME_rep3	NC 000003.				CLCN2	P;P;P;P;P;P	Uncertain significa	546169444
Variant	NC 000016.		PKD1	T>C		N;N	Uncertain significa	cross ID: 9
2D_OVCAR_ZD_rep1 variant	<u>NC 000012.</u>			A>G A		D;D;D;D;D;D;N	Uncertain significa	
DOVCAR_2D_rep3 Variant	<u>NC 000003.</u>			T>C T		D;D;D;D;D;D;D;D;D	Uncertain significa	
TME_OVCAR_TME_rep1 Variant	<u>NC 000005.</u>					D;D	Uncertain significa	
TME_OVCAR_TME_rep2 Variant	<u>NC 000006.</u>				GLO1	Polymorphism - automatic (P)	Uncertain significa	
TME_OVCAR_TME_rep3 Variant	<u>NC 000007.</u>			C>T		D;D	Uncertain significa	
	<u>NC 000006.</u>			C>TIC		N;N	Uncertain significa	
	NC 000019.		TRPM4	C>TIC		חיחיח	Uncertain significa Y	1

Figure 4. ArrayStar's "Experiment List" screen.

Find important variants with ArrayStar

ArrayStar automates Steps 5-6 with versatile filtering tools and rich graphical and tabular displays showing the variant results in context. Start by using the Advanced Filtering tool to filter out uninteresting variants, leaving only those worthy of further study. See the next chapter for an example of how to apply variant filtering.

Next, move to the Variant Table (**Figure 5**), which is ready for analysis and allows you to effortlessly add (or remove) data columns with information about each variant. If you checked the VAD box in SeqMan NGen, there are hundreds of columns to choose from. Many of these include links to the database entry for the variant in databases like the Mastermind Genomic Search Engine, ClinVar, dbSNP, 1000 Genomes Project, the Gene Ontology Consortium (GO), GERP, MutationTaster, PhastCons, dbNSFP, and many others.

ArrayStar is the only tool we are aware of that additionally performs an automatic cross sample analysis. If a variant is detected in one sample, the application cross checks all other samples at the same position and reports the status (variant, no variant call, no coverage) as a Variant Table column

	SNP Table								
	🛅 🎒 🔍 📆 🖳 📲 💱 🖏 🔯 Add/Manage Columns 🛛 🧱 Choose Quick-Filter: Showing SeqMan NGen Default Variants 🗸 🛐 📰								
-	Ref ID	Ref Pos	Gene Name	FC1_NA12892_03 - Called Seq	dbSNP ID	FC1_NA12892_03 - clinvar_clnsig	phyloP20way_mamm	FC1_NA12892_03	FC1_NA12892_03 - clinvar_trait
	NC 000011	116820918	APOA4	C>A C	5110	Pathogenic (5)	-0.804	0.0657	APOLIPOPROTEIN A-IV POLYMORPHISM, APOA4*1/APOA4*2
	<u>NC 000013.</u>	32332592	BRCA2	A>C A	<u>144848</u>		-0.189	0.2953	Breast-ovarian cancer, familial 2 not provided not specified +
	NC 000022	42126611	CYP2D6	C>G C		Drug response (6)	-1.01		Debrisoquine, ultrarapid metabolism of
	NC 000019	1397444	GAMT	G>A G	17851582	Benign (2)	0.079	0.0826	Deficiency of guanidinoacetate methyltransferase
	NC 000009	34649445	GALT	A>G A	2070074		0.138	0.1024	GALT POLYMORPHISM (DUARTE, D2) GALT POLYMORPHISM
	NC 000009	14816831	FREM1	G>C G	7041710	Benign (2)	-0.593	0.0985	not specified
	NC 000009	14846038	FREM1	C>G	2779500	Benign (2)	-0.441	0.6233	not specified
	NC 000009	34459027	DNAI1	G>T G	11547035	Benign (2)	-0.173	0.0686	not specified
	NC 000009	38396068	ALDH1B1	G>T	2073478	Benign (2)	1.04	0.6094	not specified
	NC 000009	38396505	ALDH1B1	G>A	<u>4878199</u>	Benign (2)	-0.526	0.9603	not specified
	NC 000009	131515483	POMT1	C>A C	11243406	Benign (2)	0.065	0.0378	not specified
	NC 000011	17498195	USH1C	C>G	1064074	Benign (2)	0.935	0.5637	not specified
	NC 000011	17593656	OTOG	G>A G	11024333	Benign (2)	-0.232	0.1651	not specified
	NC 000011	117395596	CEP164	C>G C	2305830	Benign (2)	0.807	0.3211	not specified
	NC 000015	30905361	FAN1	G>A G	4779794	Benign (2)	-0.285	0.4374	not specified
	NC 000015	50925164	AP4E1	T>C T	<u>2306331</u>	Likely benign (3)	-0.013	0.4663	not specified
	NC 000018	2707621	SMCHD1	G>A	2276092	Benign (2)	-0.167	0.6909	not specified
	NC 000018	3126813	MYOM1	A>G A	<u>1071600</u>	Benign (2)	0.145	0.1571	not specified
	NC 000018	3457609	TGIF1	C>T C	2229333	Likely benign (3)	0.892	0.0597	not specified
	NC 000018	10752668	PIEZO2	C>T C	7234309	Benign (2)	0.935	0.2724	not specified
	NC 000018	10759842	PIEZO2	C>A C	35033671	Benign (2)	0.935	0.2307	not specified
	NC 000010	1288520	NDHES7	ONTIC	11/2520	Likely benian (3)	0.8/1	0 5075	not specified V

Figure 5. ArrayStar's Variant Table displaying a selection of customizable data columns.

Further exploration of variants with Mastermind

Also accessible from ArrayStar is **Genomenon's powerful Mastermind Genomic Search Engine**, a comprehensive genomics database designed to be an essential resource for analysts faced with data uncertainty. Mastermind allows you to quickly and easily search and cross-reference variant data from millions of PubMed articles. Additionally, Mastermind provides entries for millions of variants that are not included in databases such as HGMD and differentiates them with much higher precision.

Mastermind enables access to millions of full-text articles encompassing the entire breadth and depth of published genomic evidence. Using patented algorithms, Mastermind allows you to filter and prioritize relevant articles with high specificity, without compromising sensitivity. Additionally, Mastermind is able to draw genetic associations between keywords (e.g., genes, variants, diseases, CNVs, phenotypes, and therapies) and deliver a segmented literature output that has been customized for your particular case.

The successful use of this tool should result in a highly useful yield of evidence surrounding your variant of interest. On the other hand, if your results are limited in Mastermind, you can be assured that limited data exists.

Optional Analysis in Lasergene

After identifying important variants using ArrayStar and Mastermind, you can use other integrated Lasergene applications to visualize your assembly read alignment and coverage and/or model mutations on protein structure (see Step 7 in Chapter 2).

To conclude this section, we have provided a table contrasting the time and number of steps to perform variant analysis with DNASTAR software and with competing software. In the next chapter, we'll show you an example of how to combine the filtering in ArrayStar and Mastermind to home in on variants of interest in clinical sequencing data.

Table 1. Typical steps involved in the variant analysis workflow using DNASTAR versus other software tools, with average elapsed time to complete the workflow, including both hands-on and compute time.

Other Pipelines	Lasergene Genomics and Mastermine
 1. Import & clean up sequencing data Import FASTQ Assess data & remove flawed portions 	
 2. Align reads to a reference genome Align reads to a reference genome Local realignment 	
3. Remove PCR duplicates	Assembly and Variant Detection in SeqMan NGen
 4. Call variants and INDELs Call variants Call INDELS Remove marginal variants Import VCF and identify known variants Import allele and genotype frequencies Predict amino acid changes Import variant databases, including Mastermind Genomic Search Engine Multiple functional predictions 	
5. Filter data to discover important variants	
 6. Determine how variants affect genes Cross-sample analysis Determine clinical significance using Mastermind and other databases 	Variant Analysis in ArrayStar and Mastermind
7. Visualize the impact of the variant on the 3D protein structure (optional)	Mutation Modeling in Protean 3D
Total average time: >4 hours 10+ applications	Total average time: 2 hours 3 integrated applications

20

Chapter 3

Use Case with Lasergene Genomics & Mastermind Genomic Search Engine

A recent collaboration between DNASTAR and Resonant Therapeutics used RNA-Seq Illumina reads to study gene expression differences in ovarian carcinoma cells (OVCAR-2 cell line) grown using 2D and 3D cultures. In case these terms are unfamiliar, a 2D culture is where cells are grown in a petri dish, while a 3D culture is grown on a matrix that mimics the microenvironment of a tumor. In this study, we show how to quickly reduce a large data set down to three variants of interest, and then demonstrate the utility of Genomenon's Mastermind Genomic Search Engine for exploring deleterious variants.

Setting up and running the assembly in SeqMan NGen

SeqMan NGen was used to align Illumina RNA-Seq data from multiple replicates to the GRCh38. p2 human genome package. In addition to read alignment, the following steps were performed automatically during the assembly process:

- 1. SNPs and other small variants were called using the diploid model
- 2. Variants were annotated using the Variant Annotation Database (VAD)
- 3. Differential gene expression values were calculated using DESeq2

This study involved cancer cells, which understandably have a large number of mutations. During assembly, SeqMan NGen called 965,209 variants.

Filtering Variants in ArrayStar

After assembly in SeqMan NGen, we used the Advanced Filtering feature in ArrayStar to identify variants found in all six experiments that met the following criteria (**Figure 6, next page**):

- General tab Non-synonymous SNPs only
- Statistics tab Pnotref > 90%, SNP% > 15, Depth > 20
- Pathogenicity tab Labeled in the ClinVar database as Pathogenic or Likely Pathogenic

Figure 6. Selections made i	n ArrayStar's "Advanced	Filtering" dialog.
-----------------------------	-------------------------	--------------------

Search Criteria:			
Search for: O Genes		Genes: All	~
Match all of the following O Match any of the following			Clear
+ - SNP Sample Group V Find SNPs in Exactly V	6 ← of 6 experiments: 2D_2D_OVCARS_rep1 Variar ∨	Choose SNP Criteria	

Figure 6a. Filtering dialog

P Searching Criteria ×	
NP Selection Criteria Summary: Non-synonymous	
eneral Statistics Population Genetics Functional Prediction Evolutionary Conservation Pathogenicity	
SNP Type V	
SNP Genotype V	
SNP Class	
Called as change: Yes No Don't check	
Located in region: O Intergenic O Genic O Coding O Non-coding RNA	
In splice site: O Yes O No O Don't check	
Translation: Synonymous Substitution No-start No-stop Frameshift Inframe indel	
Within targeted regions: O Don't check Yes No	
Use Defaults OK Cancel	
i gure 6b . General filtering options with non- ynonymous filter applied.	
rnonymous filter applied.	SNP Searching Criteria × SNP Selection Criteria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00%, Depth ≥ 20, clinvar_clinsig is Likely pathogenic or Pathogenic
/nonymous filter applied. P Searching Criteria NP Selection Criteria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00%, Depth ≥ 20	SNP Selection Criteria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00% , Depth ≥ 20,
ynonymous filter applied.	SNP Selection Criteria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00% , Depth ≥ 20, clinvar_clnsig is Likely pathogenic or Pathogenic
ynonymous filter applied. P Searching Criteria NP Selection Criteria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00%, Depth ≥ 20 General Statistics Population Genetics Functional Prediction Evolutionary Conservation Pathogenicity	SNP Selection Criteria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00%, Depth ≥ 20, clinvar_closig is Likely pathogenic or Pathogenic General Statistics Population Genetics Functional Prediction Evolutionary Conservation Pathogenicity
Ynonymous filter applied. P Searching Criteria NP Selection Criteria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00%, Depth ≥ 20 Seneral Statistics Population Genetics Filter minimum P not ref 90.00 € % Require Filter minimum Q call 0.00 € % Require Filter SNP % minimum 15.00 € %	SNP Selection Criteria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00%, Depth ≥ 20, clinvar_clnsig is Likely pathogenic or Pathogenic General Statistics Population Genetics Functional Prediction Evolutionary Conservation Pathogenicity Pathogenicity Edit Current Pathogenicity Filter ClinVar Significance Data ClinVar Significance (Category)
P Searching Criteria × NP Selection Criteria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00%, Depth ≥ 20 General Statistics Population Genetics Statistics Population Genetics Filter minimum P not ref 90.00 ♥ % Require Filter minimum Q call 0.00 ♥ % Require Filter SNP % minimum 15.00 ♥ % Maximum 100.00 ♥ % Require Filter minimum depth 20 ♥	SNP Selection Criteria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00%, Depth ≥ 20, clinvar_clnsig is Likely pathogenic or Pathogenic General Statistics Population Genetics Functional Prediction Evolutionary Conservation Pathogenicity Pathogenicity Edit Current Pathogenicity Filter ClinVar Significance Data ClinVar Significance (Category)
ynonymous filter applied. P Searching Criteria NP Selection Criteria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00%, Depth ≥ 20 General Statistics Population Genetics Filter minimum P not ref 90.00 ÷ % Require Filter minimum Q call 0.00 ÷ % Require Filter SNP % Minimum 15.00 ÷ % maximum 100.00 ÷ % Require Filter minimum depth 20 ÷ Beneric On't check Present Absent	SNP Selection Citeria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00%, Depth ≥ 20, clinvar_clinsig is Likely pathogenic or Pathogenic General Statistics Population Genetics Functional Prediction Evolutionary Conservation Pathogenicity Pathogenicity Edit Current Pathogenicity Filter ClinVar Significance Data ClinVar Significance Data ClinVar Significance Clategory) Lectinvar_clinsig ClinVar Significance Clategory) Edit Current Pathogenicity filter set Each criteria listed below will be AND'd together during filtering. Clinvar_chisg is Likely pathogenic or Pathogenic
Anonymous filter applied. P Searching Criteria NP Selection Criteria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00%. Depth ≥ 20 General Statistic Population Genetics Fulter minimum P not ref 90.00 % Require Filter minimum Q call 0.00 % maximum 100.00 % Require Filter minimum Q call 0.00 % maximum 100.00 % Bequire Filter minimum depth 20 Require Bon't check Present Absent User VCF: @ Don't check Present Absent (Provided in SeqMan NGen assembly)	SNP Selection Criteria Summary: Non-synonymous, P not ref ≥ 90.00%, SNP % ≥ 15.00% and ≤ 100.00%, Depth ≥ 20, clinvar_clnsig is Likely pathogenic or Pathogenic General Statistics Population Genetics Functional Prediction Evolutionary Conservation Pathogenicity Pathogenicity Edit Current Pathogenicity Filter ClinVar Significance Data ClinVar Significance Category) ClinVar Significance (Category) ClinVar Significance (Category) Current Pathogenicity filter set Each criteria listed below will be AND'd together during filtering.

Figure 6d. Pathogenecity filtering options with ClinVar filter applied.

ArrayStar found three variants that fit all criteria (Figure 7).

Figure 7. The three variants of interest found after filtering in ArrayStar.

Search Results				
🖪 🗖 🔊 🛅				
Ref ID	Ref Pos	Ref Seq	_	enes
NC 00 Select and	Show Results	in Variant Tab	le	PRJ;PTPRJ;PTPRJ;PTPRJ
NC 000012.12	25245350	С	KR	AS;KRAS;KRAS;KRAS
NC 000023.11	120626774	A	C1	GALT1C1;C1GALT1C1
<				
# Variant found: 3				

Looking at these results in the Variant Table, we were able to see the SNP base and reference bases, the number of articles found in Mastermind, links to that evidence, the clinvar_trait, and the MutationTaster_pred. For legibility in this ebook, the Variant Table has been split in half to create two figures (**Figures 8 and 9**).

Figure 8. The leftmost columns in ArrayStar's Variant Table.	
--	--

E	III SNP Table									
	🛅 🎒 🗋 📬 🖓 + 🖏 📬 🏂 Add/Manage Columns 📰 Choose Quick-Filter: Showing Selected Variants									
	•	Ref ID	Ref Pos	Gene Name	2D_2D_OVCARS_rep1 Variant - Called Seq	MM Citation Count	Mastermind Page Link			
	\checkmark	NC 000011	48123823	PTPRJ	A>C A	32	Show NC 000011.9:g.481453			
	\checkmark	NC 000012	25245350	KRAS	C>A	4091	Show NC 000012.11:g.25398			
	\checkmark	<u>NC 000023.</u>	120626774	C1GALT1C1	A>T	11	Show NC 000023.10:g.11976			

Figure 9. The rightmost columns in ArrayStar's Variant Table, along with a tooltip for the selected variant and a view of the Details panel.

2D_2D_OVCARS_rep1 Variant - clinvar_trait	2D_2D_OVCARS_rep1 Variant - MutationTaster_pred	SNP Table 3 of 965,209 variants displayed
arcinoma_of_colon	Polymorphism - automatic (P)	Filter: Selected variants
erebral_arteriovenous_malformation Acute_myeloid_leukemia Nevus_sebaceous Juve		
👌 Iyagglutinable_erythrocyte_syndrome	Polymorphism - automatic (P)	
NC_000012.12 @ 25245350 Variant information in experiment 2D_2D_OVCARS_rep1 Variant aaAlt: V in KRAS;KRAS;KRAS;KRAS Allele Depths: A:644 Amino Acid Change: p.G12V Called Seq: C>A Classification: Non-synonymous Contig Pos: 25246552		
Genotype: Homo. Variant Type: SNP		Details Selected variant: NC_000012.12 @ 25245350
Depth: 644 P not ref: 100.00 % Q call: 60.000 SNP %: 100.00 %		1 selected variant: Ref ID: NC_000012.12 Ref Pos: 25245350 Ref Seq: C Genes: KRAS;KRAS;KRAS;KRAS
Mastermind: MM: Gene: KRAS, HGVS: NC_000012.12:g.25245350C>A,NC_000012.11:g.25398284C>A, II MM: Count 1: 651, Count 2: 4055, Count 3: 4091	D 3: KRAS:G12V,KRAS:G12fs	phyloP100way_vertebrate: 7.89 phastCons100way_vertebrate: 1 GERP++_RS: 5.68 codonpos: 2 Interpro_domain: Small GTP-binding protein doma
Functional Predictions: LRT: pred: Deleterious (D) in KRAS;KRAS;KRAS;KRAS, score: 0 in KRAS;KRAS;KRAS;KRAS MutationTaster: pred: Disease causing (D) in KRAS;KRAS;KRAS;KRAS, score: 1 in KRAS;KR SIFT: pred: Damaging (D) in KRAS;KRAS;KRAS;KRAS, score: 0.007 in KRAS;KRAS;KRAS;KRA		GERP++_NR: 5.68 refcodon: GGT SiPhy_29way_logOdds: 18,4 phastCons30way_mammalian: 1 phyloP30way_mammalian: 1.01
Pathogenicity: clinvar: clnsig: Pathogenic, id: 12583, trait: Cerebral_arteriovenous_malformation Acute_myeloid_leukemia Nevus_sebaceous Juver ng cancer Neoplasm of the thyroid gland Neoplasm of the large intestine Carcinoma		aaPos: 12 aaRef: G Gene Name: KRAS dbSNP ID: 121913529 cross ID: 586673

Exploring Genomic Associations with Mastermind

Note that the variant in the KRAS gene (middle of the three variants) has over 4,300 Mastermind citations. This well-known variant, located on chromosome 12 at position 25245350, causes the G12V change in the KRAS protein and is the key driver mutation behind the tumors being studied. In addition to the two-star status of this SNP in ClinVar, notice that all three functional prediction methods present in the VAD also flag it as deleterious. As shown near the bottom of the tooltip, this KRAS gene mutation has been associated with a wide variety of cancers.

ArrayStar includes a direct link to Mastermind, where we can view the entry for known KRAS mutations (**Figure 10**).

	MASTERM	IND [®] Professional Edition	n			Home	Contact Us Alerts ► AP	І Му Ассо	ount▶ H	Help 🕨 📍
	GENE KRAS ×	AND VARIANT KRAS:p.G12	/× × Q Filter Categ	gorie	s 🕶 Full-text and Suppl	emental -	Share Explore A	ssociations	E Foc	cus View 👁
		1.3k Total variants in KRAS				4.3k Artic	les from full-text and suppleme	ntal		
• VARIA	ANT DIAGRAM		Select Gene: KRAS -	ſ	▼ PUBLICATION HISTOF	RY				_
000'1 001'1 000 001 001 001 001 001 000 000'1	Re 0 20 4	0 60 80 100 120 use pointer left and right to move the diagram around. Scroll th	140 160 180 e mouse to zoom in and zoom out.		100 Contractions 100 100 100 100 100 100 100 100 100 10	2014 2015			elevance article	
• VARIA	ANTS Filter by: V600	E, 600, c.1799T>A, fs, deltaF508, etc.	🗌 Hide Zero		▼ ARTICLES ▲ Export	C Google Schol	ar 🗗 Varsome 🗿 🕲 Q Filter	Sort by:	Relevance	• 🔹 🖬
ENE	VARIANT		ARTICLE MATCHES		JOURNAL	DATE	TITLE			:p.G12V ▼
KRAS	p.G12V	c.34, c.35, c.36 <u>More info</u> ▶	<u>4.3k</u> <u>4.3</u> k		Sci Rep	2020 Oct 20	Neuron type-specific expression of		1 186	
KRAS	p.G13D	c.37, c.38, c.39 <u>More info</u> ⊧	<u>3.1k</u> <u>1.9</u>	≤	Cancers (Basel)	2020 May 30			1 241	
KRAS	p.G12C	c.34, c.35, c.36 <u>More info</u> ▶	<u>2.9k</u> <u>1.8k</u>	5	Front Immunol	2019 Nov 15	An in silico-in vitro Pipeline Identify	ing an HLA	1 162	1 126
KRAS	p.G12S	c.34, c.35, c.36 <u>More info</u> ▶	<u>1.7k</u> <u>1.2k</u>	<u><</u>	🗈 Sci Rep	2020 Nov 26	Differences in gynecologic tumor d	evelopment i	1 66	1 109
KRAS	p.G12A	c.34, c.35, c.36 <u>More info</u> ▶	<u>1.5k</u> <u>1.2k</u>	<u><</u>	Cancers (Basel)	2019 Dec 1	Proteogenomics of Colorectal Can	cer Liver Met	1 159	1 112
KRAS	p.G12R	c.34, c.35, c.36 <u>More info</u> ▶	<u>1.3k</u> <u>1.0</u> k	<u><</u>	E Circ Res	2020 Jun 17	Somatic Gain of KRAS Function in	the Endothel	1 196	1 65
KRAS	n 061H	0 181 0 182 0 183 More info k	087 620	h	Cancers (Basel)	2020 Mar 31	The Inhibition of Wnt Restrain KRA	S ^{G12V} -Driven	1 275	1 129

Figure 10. The Mastermind Professional Edition landing page for the KRAS G12V variant.

Optimize output with prioritized sorting and filtering

The image on the previous page shows the full list of over 4,300 publications citing this variant. The literature base can then be focused by adding phenotype keywords. In this case, when "ovarian carcinoma" is applied, the reference number is reduced to 140 articles (**Figure 11**).




Figure 11. Mastermind KRAS G12V with ovarian carcinoma phenotype applied.

Other filters may be used to further refine this search, including expression filters in the "Genetic Mechanism" tab (**Figure 12**).

Figure 12	Mastermind	Filters	including	expression
-----------	------------	---------	-----------	------------

enetic Mechanism	Enable All	Variant	Disable All		
ariant	43 Met	1 Val			
opy number 35 Pro		2 Thr	- Ala		
sion events	з Туг	¹⁹ Stop	26 His		
igenetics	2 GIn	- Asn	1 Lys		
-9	1 Asp	1 Glu	4 Cys		
	1 Trp	2 Arg	³ Gly		
	65 expression		Enable All Disable A		
	³ decreased expression	¹⁰ down-regulated	24 downregulation		
	10 down-regulated	20 downregulated	7 elevated expression		
	17 increased expression	7 lower expression	9 reduced expression		
	32 upregulation	16 up-regulation	18 up-regulated		
	27 upregulated				

This focuses the results on 65 highly relevant articles (Figure 13).

GENE	KRAS ×		Ovarian × 🗶 Q 1 Filtered C	ategory - × F	Full-text and Supplemental▼ < Share Explore Associations \= Focus View ●
_					
		1.3k Total variants in KRAS			65 Filtered articles from full-text and supplemental
VARIA	NT DIAGRAM		Select Gene: KRAS 👻 🖬	▼ PUBLICATIO	IN HISTORY
Citations per Variant (0 01 01	Per 20	40 60 80 100 120	140 160 180	100 Reset	Lower relevance articles not shown
VARIA		/600E, 600, c.1799T>A, fs, deltaF508, etc.	Hide Zero	- ARTICLES	Sexport [2] Google Scholar [2] Varsome O O Q Filter Sort by: Relevance
ENE	VARIANT	♦ CDNA POSITIONS	ARTICLE MATCHES	Autophag	gy 2015 Jan 1 Disruption of the ribosomal P complex leads to 1 3 1 1
nau	p.0120	0.04, 0.00, 0.00 <u>Wore Into P</u>		Cancers ((Basel) 2020 May 30 A H-REV107 Peptide Inhibits Tumor Growth an 1 241 1 137
RAS	p.G12V	c.34, c.35, c.36 <u>More info</u> ▶	4.3k 65 65	Oncotarge	get 2018 Jan 10 Dimethyl fumarate is highly cytotoxic in KRAS 1 73 1 14
RAS	p.G12C	c.34, c.35, c.36 <u>More info</u> ▶	<u>2.9k 41 24</u>	E Expert Op	pin Investig Dr 2017 Jul 12 Selumetinib for the treatment of non-small cell I 1 172 1 18
RAS	p.G13D	c.37, c.38, c.39 More info >	<u>3.1k 37 22</u>	Int J Mol 5	Sci 2020 Jun 17 Targeting KRAS Mutant Non-Small-Cell Lung C 1 284 1 10
P49	n G129	0.34 0.35 0.36 Mars info h	176 18 19		
PUBM	ED DATA PMIC	D: ⊡ 26176264	_	▼ FULL-TEXT I	MATCHES PMID: C 26176264 PDF Show: All matches V
isruptio	n of the riboso	omal P complex leads to stress-induced aut	ophagy.	TYPE ENTITY	Y MATCHED TEXT
utophag	У	2014 Dec 31	Artero-Castro A	gene KRAS	KRAS initiation factor 2-α kinase 3; EIF2S1/EIF2 α; ER, endoplasmic reticulum; G6PD
		lex, which consists of the acidic ribosomal P proteins RP I factors, facilitating protein synthesis. Recently, we show		gene KRAS	Kirsten rat sar, Kirsten rat sarcoma viral oncogene homolog; KRT17, keratin 17, type I; LCM
		contributes to transformation. Moreover, RPLP proteins		keyword downre	regulated - downregulat Here, we report a distinct mechanism by which cancer cells undergo cell cycle
		preast carcinomas. It is thought that disruption of the P co		keyword upregu	
ynthesis, c	0 0	arrest and eventually apoptosis. Here, we report a distin- induced autophagy when RPLP proteins are downregulat		gene KRAS	

Figure 13: Mastermind KRAS G12V Filtered by phenotype, expression and relevance

The articles displayed are sorted by relevance, with the larger circles in the publication history pane denoting the most relevant articles. Relevance is determined by several factors, including, but not limited to:

- The number of times in which the gene ("KRAS") and variant ("G12V") names are mentioned in each article,
- Whether these terms are in the title, abstract and/or full text or supplemental information, and
- Proximity to phenotype and other keywords applied through the filtering process.

All of these elements can be viewed in the "Full Text Matches" section by viewing all matches being highlighted in the sentence fragments.

Uncover data connections with genomic associations

Due to the highly complex nature of genetic disorders and the variety of factors that contribute to their pathogenicity, the opportunity to create clarity around how your search criteria of interest relate with each other is exceedingly beneficial. The Genomic Associations functionality within Mastermind allows you to explore significant genetic associations that may otherwise be missed or unrecognized, giving you the ability to uncover key data that may lead to a new hypothesis, a research discovery, or even solving a clinical case.

To expand on the example, suppose that you are interested in exploring treatment options for ovarian carcinoma related to KRAS p.G12V mutations. Clicking on the blue "Explore Associations" box (**Figure 14**) directs you to a flexible interface that connects your search keywords with all associated genetic factors in the medical evidence.

Figure 14. The Explore Associations box on the Mastermind page.

MASTERMIND [*] Professional Edition	Home Contact Us Alerts API My Account Help + 📍
GENE KRAS X AND VARIANT X AND PHENOTYPE	Ovarian 🗴 🗶 Q 1 Filtered Category 🗸 🗴 Full-text and Supplemental 🗸 Share Explore Associations 🗐 Focus View 👁
1.3k Total variants in KRAS	65 Filtered articles from full-text and supplemental

In this case, the "Therapies" tab reveals prioritized articles covering therapeutic intervention for KRAS p.G12V-related ovarian carcinoma. As seen in Figure 15, in terms of article quantity, the top three pharmacotherapies are:

- 1) Paclitaxel
- 2) Selumetinib
- 3) Carboplatin

Image: MASTERMIND* Professional Edition Home Contact Us Alerts + API My Account + Help + A											
GENE KRAS × AND	VARIANT KRAS:p.G12V × AND	PHENOTYPE Ova	ian carcinoma × 🛛 🗙 🕻	Q Filter Categories →	Full-text and Supple	mental -		Share View Evidence 🗎			
Welcome to the new Genomic Associations interface. Learn how to use this powerful tool in our blog.											
Genes Variants Diseases Phenotypes Therapies CNVs Association Tabs											
Additional Associations Additional Associations Click *Add t Therapies mentioned in articles matching your search criteria are displayed in this column. Counts for additional associations mentioned in articles matching your search criteria are displayed in these columns, such as additional gene or disease associations. Click the count for a given therapy to add to your search criteria and view those associations as a new list. Click *Add t Therapies Output Therapies Output Mentional associations Mentional associations Mentional associations											
THERAPY 1.3K	ARTICLES 140	GENES	VARIANTS	DISEASES	PHENOTYPES	OTHER THERAPIES	CNVS	ACTIONS			
GTPASE KRAS G12D MUTANT	34	1.6k	35	66	430	500	142	+ Add to search 🗟 View evidence			
PACLITAXEL	28	999	26	39	368	449	123	+ Add to search 📄 View evidence			
SELUMETINIB	26	524	23	31	349	363	47	+ Add to search 🗈 View evidence			
CARBOPLATIN	23	851	26	36	360	375	152	+ Add to search 🗈 View evidence			
EPIDERMAL GROWTH FACTOR RECEPTOR	23	928	24	37	477	611	101	+ Add to search 🗈 View evidence			
TRAMETINIB	22	518	20	32	372	363	64	+ Add to search 🔒 View evidence			
SIROLIMUS	21	939	16	45	487	508	175	+ Add to search 🗟 View evidence			
BEVACIZUMAB	20	673	15	36	426	371	76	+ Add to search 🗟 View evidence			
NEPIDERMIN	20	1.1k	16	44	465	528	97	+ Add to search 📄 View evidence			
DOCETAXEL	18	763	13	27	441	440	106	+ Add to search 🗎 View evidence			
CISPLATIN	18	759	27	26	425	409	117	+ Add to search 📄 View evidence			
GEMCITABINE	17	613	25	30	369	416	93	+ Add to search 🗟 View evidence			

Figure 15. The "Therapies" tab with the top three pharmacotherapies boxed in orange.

Awareness of therapies surrounding a particular genetic variant creates informed focus during hypothesis formation and study design. Most importantly, however, this invaluable insight significantly impacts clinical decision making by adding precision to patient care.

Finally, although these patient-facing applications are compelling, they represent a small fraction of this technology's complete potential: as evidenced by the other five association tabs, there's much more for Lasergene and Mastermind users to discover.

Conclusion

Next-generation sequencing (NGS) of whole genomes, exomes, and RNA-Seq data is a powerful tool in biomedical research and diagnostics. However, sifting through the vast amount of NGS data to find the most relevant variants can be like looking for a polar bear in a snowstorm. Incorrect or deficient annotations can cause you to overlook potentially disease-causing variants. Open source and commercial tools have been developed to address this issue, but often, a dozen or more unrelated tools must be mastered in order to perform the analysis.

In response, DNASTAR has developed Lasergene Genomics, a fully integrated variant analysis and annotation pipeline with an intuitive, easy-to-use interface. Lasergene Genomics and its Variant Annotation Database greatly simplify variant analysis so that you can get accurate answers without needing a PhD in bioinformatics. With the recent addition of the powerful Mastermind Genomic Search Engine, the once time-consuming job of variant analysis is now faster, easier, and more accurate than ever before.



CONTACT US

To see a demo of the software, or to learn more about how Lasergene Genomics and Mastermind can fit into your research, email or call us at one of the numbers listed below.

www.dnastar.com Email: sales@dnastar.com Phone: 608.258.7420 Toll Free in the U.S. and Canada: 866.511.5090 Call free in the UK: 0.808.271.1041 Call free in Germany: 0.800.182.4747

DNASTAR 30